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Class I proteins of the major histocompatibility complex play a central role in
the lysis of virus infected or allogeneic cells by cytotoxic T lymphocytes (CTL)
(1) . Analysis ofmutant class I molecules generated in vivo or in vitro has defined
residues involved in recognition by T cell receptors and monoclonal antibodies .
In general the determinants recognized by antibodies (B cells) and T cells have
been found to be different . For example, naturally occurring mouse and human
class I variants detected by CTL display few or no changes in antibody binding
(2, 3) . Substitutions at positions of variability dispersed throughout the a, and
a2 domains of human and murine class I molecules have been shown to affect
CTL recognition . These include positions 147-157, a region having a complex
pattern of substitutions in the mouse bml mutant and in HLA-A2 and HLA-A3
subtypes, and position 116, which is altered in five of the bm mutants and in
HLA-B7 subtypes (4-6) .
Similarly, mutations in class I molecules which affect antibody reactivity do
not always alter the recognition by CTL (7) . For example HLA-A2 mutants
obtained by negative selection with the HLA-A2, Aw69-specific monoclonal
antibody, BB7 .2, were indistinguishable by CTL from the wild type molecule,
although they no longer bound BB7.2 (7) . Structural analysis indicated that
changes at position 161 and in the peptide corresponding to positions 98-108
occurred separately in two of the mutants (5) . Comparison of amino acid
sequences has shown that HLA-A2 and HLA-Aw69, which are the only two
molecules to bind 13137 .2, share a tryptophan at position 107 within this latter
region (8) . All other HLA class I molecules analyzed contain glycine at this
position (9) . These results suggested that tryptophan 107 is crucial in forming
the epitope recognized by BB7.2 . Here we report experiments to directly test
this hypothesis and to determine how substitution at this position affects recog-
nition by alloreactive CTL .
Materials and Methods
Mutagenesis .
￿
Site-directed mutagenesis was performed as described (10) using a 5.1
kb Hind III fragment of the HLA-Aw68 gene (8), which was subcloned into the vector
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FIGURE 1 .
￿
Amino acid sequences of the a, and a2 domains of the HLA-A2/A28 family (17)
and of the two mutants derived from HLA-Aw68.1 . All sequences are compared to HLA-
A2.1 .
pTZ 19 (Pharmacia Fine Chemicals, Piscataway, NJ). Oligonucleotides were synthesized
with an Applied Biosystems automated synthesizer.
Transfection.
￿
Class I geneswere subdoned into the vector pHEBO (11) using the Hind
III site. 20 jAg of DNA was transfected into 5 X 106 Hmy 2 CIR B lymphoblastoid cells
by electroporation (12). Hmy 2 CI R is an HLA-A, B-negative derivative of LicrLon Hmy
2 (13). After 4 wk in culture with 200 Icg/ml hygromycin B, >90% of transfected cells
reacted with the HLA-A2, A28-specific monoclonal antibody CR11 351 (14) in flow
cytometry. Cell cultures continued to stably express the transfected genes thereafter.
Analysis.
￿
Cell binding radioimmunoassays were performed with monoclonal antibodies
MB40.5, PA2.1, CR11-351, BB7.2, and Tu160 (gift of Dr. Andreas Ziegler) as described
(14, 15). CTL were derived from the line AJY and assayed as described (16). In inhibition
assays peptides were preincubated for 30 min with 5 X 103 CTL (clones AP23.1 and
ATL8.1) or 3 X 103 CTL (clone AP31.1) before addition of 103 "Cr-labeled target cells.
The peptides were present throughout the assay period of 3-5 h (9).
Results and Discussion
Analysis with antibodies and CTL has defined a series of HLA-A molecules
related to HLA-A2 and called the HLA-A2/A28 family (17). The amino acid
sequences of six members of this family in the two most variable domains (a,
and a2) are shown in Fig. 1 . Within this family, HLA-A2.1 and HLA-Aw68 .1
are least homologous, differing by six amino acids in both the a, and a2 domains
(Fig. 1). Other members of the family (HLA-A2.2Y, -A2.3, -Aw68.2) contain
intermediate numbers of substitutions. HLA-Aw69 is a recombinant composed
of an a, domain of HLA-Aw68.1 and a2 and as domains of HLA-A2.1 (8).
Correlation of antibody reactivity with the primary structure identified trypto-
phan 107 as a candidate for involvement in epitopes shared by HLA-A2 .1,
-A2.2Y, -A2.3, and -Aw69, but not present in HLA-Aw68.1 and -Aw68.2 . This
hypothesis was directly tested by introducing this residue into HLA-Aw68.1 by
site-directed mutagenesis. A second mutant was generated by replacing isoleucine
and methionine residues at positions 95 and 97 of HLA-Aw68.1 with the
corresponding valine and arginine residues of HLA-A2 .1 (Fig. 1).
The two mutants and the wild type HLA-Aw68 .1 gene were transfected into
the B lymphoblastoid cell line Hmy2 CIR, which was chosen for its low level of
class I antigen expression. The binding of monoclonal antibodies to these
transfectants is shown in Fig. 2. Monoclonal antibodies such as CR11-351, whichAntibody Specificity
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Recognition of HLA-Aw68.1 mutants by monoclonal antibodies and CTL. (A)
RIA of Hmy CIR transfectants containing the pHEBO vector alone (A), HLA-Aw68.1 (B)
mutant 95-97 (C) or mutant 107 (D) genesin pHEBO, and oftheA2+ B cell lines JY (E). (B)
CTL analysis performed with the panel of cells used in A. Labeled target cells were incubated
for4 h with effector cells at the following E/T ratios:Clones ATL8.1,AP31.1, and APW 15,
E/T = 1.2; clone AP23.1, E/T = 5; clone AM8B.2, E/T = 2. The class II-reactive CTL line
CCD was used at E/T = 1.2. Clone AM8B.2 is reactive with an epitope in the a, domain of
HLA-A2, whichis shared with HLA-B17, but not HLA-Aw68. Clone APW 15 was used as a
control to show that all three transfectants bearing HLA-Aw68.1-derived molecules could be
lysed. Monoclonal antibodies directed against class I determinants presenton target cellswere
able to block lysis by each class I-reactive clone, whereas an antibody specific for class II
antigens was not(data not shown).
are specific for epitopes shared by HLA-A2, Aw68, and Aw69, bound strongly
to cells transfected with HLA-Aw68.1 and both mutant genes. This showed that
the transfected genes were being expressed. The HLA-A2, Aw69-specific anti-
bodies PA2.1, BB7.2, and Tu160 bound the mutant 107 transfectant, but not
the HLA-Aw68.1 or mutant 95-97 transfectants . This result proves that the
determinant recognized by the HLA-A2, Aw69 specific antibodies is critically
dependent upon tryptophan 107. Furthermore, the introduction of these epi-
topes into another class I molecule (i.e., HLA-Aw68.1) can be effected by this
single amino acid substitution.
It was therefore of interest to determine if epitopes recognized by CTL were
also transferred by these mutations. The transfectants expressing mutants 107
and 95-97 were tested as targets for 21 clones of CTL that lysed CIR cells
transfected with the HLA-A2.1 gene (data not shown) but did not lyse or gave286
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FIGURE 3.
￿
Inhibition of CTL clones by peptides. The combinations of CTL and target cell
lines used are labelled above the individual graphs. Peptides used are A2.98-113
(MYGCDVGSDWRFLRGY) andAw68.98-113 (MYGCDVGSDGRFLRGY) designated by
and ", respectively. At 55 ug/ml, the molar concentrations are 2.7 X 10-5 M for A2 .98-113,
and 2.9 X 10-5 M for Aw68.98-113.
weak lysis of the HLA-Aw68.1 transfectant. Four positive clones were found
(Fig. 2). Clone ATL8.1 lysed mutant 107 at a high level, and mutant 95-97 to
a lesser extent . Clone AP23.1 lysed the mutant 95-97 transfectant, but not the
mutant 107 transfectants. Clone AP31 .1 lysed transfectant 107 but not transfec-
tant 95-97, whereas clone APW.15 lysed both transfectants (Fig. 2). These
results demonstrate thatone or twoamino acid substitutions in the HLA-Aw68.1
molecule are sufficient to confer reactivity with certain HLA-A2 specific CTL
clones.
Analysis of the fine specificity of CTL clones ATL8.1 and AP31.1 showed
that their reactivity is distinct from that of the HLA-A2, Aw69-specific antibod-
ies. First, neither CTL lysed cells expressing HLA-Aw69, and other CTL that
recognize HLA-Aw69 failed to lyse transfectant 107. Second, these CTL lysed
other members, e.g., HLA-Aw68.2 of the HLA-A2/Aw68 family, whereas the
antibodies are specific to HLA-A2 and HLA-Aw69.
We have previously shown that tryptophan 107 is a critical residue for the
inhibition of CTL given by synthetic peptides. A peptide (A2.98-113) corre-
sponding to residues 98-113 inhibits lysis of HLA-A2 bearing targets by CTLSALTER ET AL.
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specific for HLA-A2. In contrast, asecond peptide (Aw68.98-113) derived from
the same region of HLA-Aw68.1, and which only differs by the tryptophan to
glycine change at position 107 did not affect lysis (9). The mechanism of this
inhibition is not known and may occur at the surface of either the CTL and/or
the target cell. To see if inhibition was dependent upon the presence of trypto-
phan 107 in the target class I molecule we tested the capacity of peptides A2.98-
113 and Aw68.98-113 to inhibit the lysis of mutant transfectants 107 and 95-
97 by A2-specific CTL. The lysis ofan HLA-A2.1 expressing cell line (JY) byall
three CTL tested was specifically inhibited by A2.98-113. CTL AP31.1, which
is specific for transfectant 107 but not 95-97, and CTL AP23.1, which isspecific
for transfectant 95-97 but not 107 were both inhibited by peptide A2.98-113
on the appropriate transfectant target. This shows that the presence of trypto-
phan 107 in the target class I molecule is not a necessary requirement for the
peptide inhibition. Neither is it a sufficient requirement, as shown by the results
with CTL ATL8.1, which was inhibited by the peptide on JY but not on mutant
107.
These results show that a region encompassing residues 95-107 at the NH2-
terminal end of the a2 domain of HLA-A2 is important in forming epitopes
recognized both by monoclonal antibodies with polymorphic specificity and by
alloreactive CTL. In the case of position 107, a single substitution is capable of
introducing novel B and T cell defined epitopes of HLA-A2 into the HLA-
Aw68.1 molecule. We do not know whether tryptophan 107 directly interacts
with the combining sites of the relevant antibodies and CTL receptors or if it
produces conformational changes at a separate site that is responsible for these
interactions. Prediction of secondary structure shows that position 107 has a
high probability of being involved in a turn at the surface of class I molecule,
favoring the model ofdirect interaction.
Summary
We have studied the interaction of HLA class I antigens with alloreactive
cytotoxic T lymphocytes and monoclonal antibodies usingsite-directed mutagen-
esis and expression of an HLA-Aw68.1 gene. Two mutants containing distinct
substitutions at polymorphic residues near the NH2-terminal end of the a2
domain were made. One mutant with substitutions at positions 95 and 97
corresponding to residues found in HLA-A2.1 showed no alterations in binding
ofHLA-Aw68- or HLA-A2-specific monoclonal antibodies, but was reactive with
some HLA-A2-specific CTLclones. A second mutant, in which glycine at position
107 was replaced with tryptophan found at that position in HLA-A2.1, was
recognized by HLA-A2-specific CTL clones and HLA-A2, Aw69-specific mono-
clonal antibodies. Thus, substitution of a single amino acid residue at position
107 ofthe HLA-Aw68.1 molecule generates an allospecific determinant shared
with HLA-A2.1 and recognized by both B and T lymphocytes.
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Note aded in proof Similar results have been reported by Layet et al. (18) showing that the epitope
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